@Bazsa, I agree with everything you say except at the end. The current trial is to evaluate remestemcel-L as a treatment specifically for the ARDS of Covid-19. It's possible to have ARDS from a variety of other causes, both infectious and non-infectious. But to get into the rem-L trial a patient must have evidence of infection with the virus that causes Covid-19. So in these Covid-19 cases the ARDS is a manifestation of a more severe form of the disease, next stop multi-organ failure / death. Remestemcel-L may be useful for some of the other causes of non-C-19 ARDS. That will be worked out through clinical experience and perhaps additional clinical trials down the road.Inclusion Criteria
- 18 years or older
- Patient has coronavirus disease COVID-19 confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or other diagnostic test
Patient requiring mechanical ventilatory support with moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria)
- Bilateral opacities must be present on a chest radiograph or computed tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.
- Respiratory failure not fully explained by cardiac failure or fluid overload.
- Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:
- Moderate ARDS: PaO2/FiO2 >100 mmHg and ≤200 mmHg, on ventilator settings that include PEEP ≥5 cm H2O OR
- Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm H2O
- High sensitivity C-Reactive Protein (hs-CRP) serum level >4.0 mg/dL
- Acute Physiologic and Chronic Health Evaluation (APACHE IV) score >5
- The patient or his/her legally authorized representative (LAR) is able to provide informed consent
- Forums
- ASX - By Stock
- MSB
- Investors in MSB / MESO competitors research us
Investors in MSB / MESO competitors research us, page-43
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B |
Open | High | Low | Value | Volume |
$1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 14424 | 99.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 63643 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1010 | 1.000 |
4 | 12123 | 0.995 |
3 | 25995 | 0.990 |
1 | 3300 | 0.985 |
3 | 43077 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
0.950 | 13134 | 2 |
1.000 | 3900 | 2 |
1.010 | 29000 | 3 |
1.015 | 37636 | 2 |
1.020 | 114623 | 6 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |